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Estrogen replacement promotes cutaneous wound healing in 8–10-week young ovariectomized female mice. However, research
using aged ovariectomized female mice has not been reported, to the best of our knowledge.Therefore, we investigated the effect of
17𝛽-estradiol on cutaneous wound healing using 24-week middle-aged ovariectomized female mice. Twenty-week-old female mice
were divided into three groups: medication with 17𝛽-estradiol after ovariectomy (OVX + 17𝛽-estradiol), ovariectomy (OVX), and
sham (SHAM). After 4 weeks, themice received two full-thickness wounds.Then, the OVX+ 17𝛽-estradiol groupwas administered
17𝛽-estradiol at 0.01 g/day until healing. The ratio of wound area in the OVX + 17𝛽-estradiol group was significantly decreased
compared with that in the OVX group. The numbers of neutrophils and macrophages in the OVX + 17𝛽-estradiol group were
significantly smaller than those in the OVX group. In addition, the ratio of myofibroblasts in the OVX + 17𝛽-estradiol group was
significantly higher than that in the OVX group. These data suggested that exogenous continuous 17𝛽-estradiol administration
promotes cutaneous wound healing in 24-week OVX female mice by reducing wound area, shortening inflammatory response,
and promoting wound contraction. However, it is unclear whether the effect of exogenous estrogen on wound healing outweighs
the delay of wound healing due to advanced age.
1. Introduction
Cutaneous wound healing is a complex, tightly orchestrated
response to injury, carefully regulated at temporal and spatial
levels [1]. Generally, there are various overlapping phases of
the repair process (the immediate response; the inflammatory
response; the proliferation,migration, and contraction phase;
and the remodeling phase) [1].
With advanced age, this series of events becomes dis-
rupted and healing is delayed. In elderly humans, delayed
healing of acute wounds is characterized by the extension
of inflammation [2], increased protease activity [3, 4], and
delayed re-epithelialization [5]. However, postmenopausal
women with systemically reduced estrogen heal poorly
[5], whereas exogenous estrogen treatment reverses this
delayed cutaneous wound healing by dampening excessive
neutrophil recruitment [6], promoting re-epithelialization
[5] and increasing collagen deposition [5–7].
Rodent models subjected to ovariectomy (OVX) consti-
tute a cornerstone in elucidation of the effects and detailed
biological mechanisms of estrogen. OVX exhibited delayed
cutaneous wound healing compared with SHAM [5, 6, 8–14],
whereas exogenous estrogen treatment reversed this delay
by decreasing wound area [5, 8, 12–14], local numbers of
neutrophils and macrophages [8–12, 14], and wound levels
of TNF𝛼 [8–12], and by promoting re-epithelialization [5, 9,
11–14], and collagen deposition [5]. However, these studies
evaluating the effects of estrogen used 8–10-week young
female mice, and research using aged female mice has not
been reported, to the best of our knowledge.
Since the relationship between advanced age and exoge-
nous estrogen treatment in relation to cutaneous wound
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healing remains unknown, we here attempt to verify the
effect of estrogen on cutaneous wound healing using an
older OVX female mouse model. We investigate the effect
of 17𝛽-estradiol on cutaneous wound healing using 24-week
middle-agedOVX femalemice.The aims of the present study
are to evaluate how 17𝛽-estradiol administration promotes
cutaneous wound healing in 24-week middle-aged OVX
female mice, and which factor has a stronger influence on
cutaneous wound healing: estrogen or age.
2. Materials and Methods
2.1. Animals. Sixty-three C57BL/6 female mice aged 8 weeks
(Sankyo Lab Service Co., Tokyo, Japan) were used in
the experiments. They were caged individually in an air-
conditioned room at 25.0 ± 2.0∘C with light from 08:45 to
20:45 hours, and water and chow were given freely. The
experimental protocol and animal care were in accordance
with the Guidelines for the Care and Use of Laboratory
Animals of Kanazawa University, Japan (AP-122316).
2.2. Wounding. The mice were bred until 20 weeks. At
this time, they were anesthetized by intraperitoneal (IP)
injection of pentobarbital sodium (0.05mg/g weight), and
the dorsum was shaved. Then, they were subjected to sham
surgery (SHAM) or ovariectomy (OVX) according to OECD
guidelines [15]. Four weeks later, they were divided into
three groups (21 mice/group): SHAM group, OVX group,
and OVX + 17𝛽-estradiol group. Then, under anesthesia
with shaving, two circular full-thickness skin wounds (4mm
in diameter) including the panniculus carnosus muscle on
both sides of the dorsum of the mouse were made with a
Kai sterile disposable biopsy punch (Kai Industries Co. Ltd.,
Gifu, Japan). In SHAM and OVX groups, the wounds were
covered with hydrocolloid dressing (Tegaderm; 3M Health
Care, Tokyo, Japan) to maintain a moist environment, and
then themousewaswrappedwith sticky bandages (Meshpore
Tape; Nichiban, Tokyo, Japan).They were changed every day.
In the OVX + 17𝛽-estradiol group, wounds received the same
treatment. However, after wound treatment, they were also
treatedwith 0.01 g of 17𝛽-estradiol gel (L’estrogel 0.06%; Bayer
Yakuhin, Osaka, Japan). It was placed on clean gauze using a
1-mL syringe and applied to the skin on the back avoiding the
wounds every day.
2.3. Macroscopic Observation. The day when wounds were
made was designated as day 0, and the process of wound
healing was observed from days 0 to 14 after wounding.
Wound edges were traced on polypropylene sheets and
photographs were taken every day. The traces on the sheets
were captured with a scanner onto a personal computer using
Adobe Photoshop Elements 7.0 (Adobe System Inc., Tokyo,
Japan), and the areas of wounds were calculated using image
analysis software Scion Image Beta 4.02 (Scion Corporation,
Frederick,Maryland, USA).Wound area is shown as the ratio
of wound area every day to the initial wound area on day 0
when the wound was made. Our previous studies reported
[16–18] that a full-thickness cutaneous wound on the back of
a mouse without any management, such as the application
of honey, daidzein, or estrogen, healed with scar formation
on about day 14 after wounding and the ratio of wound area
reached about 0.1. Therefore, we calculated the number of
wounds reaching the 0.1 ratio of wound area per group.
2.4. Plasma 17𝛽-Estradiol and Uterus Assay. The mice were
euthanized by a massive pentobarbital sodium IP injection
on day 14. Plasma was prepared from each mouse’s blood
isolated through cardiac puncture and frozen until the time
of assay.Plasma 17𝛽-estradiol levels were determined by
radioimmunoassay (RIA), and since levels less than 10 pg/mL
could not be detected, such levels were recorded as 10 pg/mL.
This was outsourced to the manufacturer of this assay
(Mitsubishi Chemical Medience Corporation, Tokyo, Japan).
The uterus was harvested according to OECD guidelines [15]
after blood isolation, its wet weight was measured, and it was
fixed in 4% paraformaldehyde and embedded in paraffin.
2.5. Plasma TNF-𝛼. The mice were euthanized by a massive
pentobarbital sodium IP injection on days 3 and 7. Plasmawas
prepared from each mouse’s blood isolated through cardiac
puncture and frozen until the time of assay. Plasma TNF-
𝛼 levels were determined by ELISA (R&D Systems, Tokyo,
Japan) according to the manufacturer’s guidelines.
2.6. Histological Procedure and Immunohistological Staining.
Themice were euthanized by amassive pentobarbital sodium
IP injection on days 3, 7, 11, and 14 after wounding. The
wound and the surrounding intact skin were harvested and
each sample of wound and surrounding intact skin was
bisected at the wound center. One-half of each wound was
stapled onto polypropylene sheets to prevent overcontrac-
tion of the sample and fixed in 4% paraformaldehyde for
12 hours. These samples were dehydrated in an alcohol
series, cleaned in xylene, and embedded in paraffin to
prepare 5 𝜇m serial paraffin sections. The remainder of each
wound was embedded in tissue-Tek OCT (Sakura Finetek,
Japan) before fixing to prepare 5-𝜇m serial ice sections. At
least 6 serial sections near the center of the wound were
obtained from one wound and stained according to the
following methods. Paraffin sections of 5-𝜇m thickness were
stained with hematoxylin and eosin (H&E) or subjected to
Azan staining and immunohistologically stained with anti-
neutrophil antibody at a concentration of 1 : 100 (Abcam
Japan, Tokyo, Japan) for detecting neutrophils, anti-Mac-3
antibody at a concentration of 1 : 100 (BDPharmingen, Tokyo,
Japan) for detecting macrophages, and cryosections of 5-
𝜇m thickness were immunohistologically stained with anti-
𝛼-smooth muscle actin (𝛼-SMA) antibody at a concentration
of 1 : 500 (Abcam Japan, Tokyo, Japan) for detecting myofi-
broblasts. Negative control slides were obtained by omitting
each primary antibody.
2.7. Microscopic Observations. Images were imported onto
a computer using a digital microscopic camera (DP2-BSW
Olympus, Japan). Measurements for the proportions lacking
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Figure 1: Uterus. (a) Macroscopic photos. A circle indicates the ovary and arrows indicate the uterus. In the SHAM group, the uterus
was thin but soft. In the OVX group, it looked thinner than that in the SHAM group and was scleroid and atrophic. On the other hand,
in the OVX + 17𝛽-estradiol group, it was hypertrophic and fresh. (b) Hematoxylin and eosin staining. In the SHAM group, histological
features included anestrus, with the epithelium invaginated to endometrium. In the OVX group, invagination of the epithelium had almost
disappeared. Otherwise, in the OVX + 17𝛽-estradiol group, proestrus was shown and the uterine cavity was extended.
re-epithelialization were performed using DP2-BSW Olym-
pus software: the distance between both wound edges and the
distance between the tips of elongated new epithelium were
measured, and then the latter was divided by the former (no
re-epithelialization length/wound length). Measurements for
collagen deposition colored blue (collagen pixels/total wound
pixels) and for myofibroblasts colored brown (myofibroblast
pixels/total wound pixels) were performed using Adobe
Photoshop Elements 7.0 as follows: the wound area was first
selected; one wound edge, the surface of the wound, the
other wound edge, and the bottom of the wound, which is
the position of the panniculus carnosus, were surrounded,
and then the number of pixels in the surrounded area (=
wound area) was calculated. Next, the collagen deposition
colored blue or myofibroblasts colored brown were selected
and the number of pixels of the blue or brown area (the
area of collagen deposition or the area of myofibroblasts)
was calculated; finally, the number of pixels of the area of
collagen deposition or the number of pixels of the area of
myofibroblasts was divided by the number of pixels of the
wound area. To analyze the numbers of neutrophils and
macrophages in the granulation tissue, each positive cell was
counted by observation through a light microscope using a
×40 objective at three sites of granulation tissue: two sites near
the two wound edges and the center of the granulation tissue.
Areas of these three sites were calculated on the monitor
of the DP2-BSW and the total number of neutrophils or
macrophages at the three sites was divided by the whole area
of these three sites.
2.8. Statistical Analysis. Data are expressed as mean ± SD
and analyzed using JMP 8.0.1 (SAS, USA). Fisher’s exact
probability test, ANOVA, and Student’s t-test or Tukey-
Kramermultiple comparison test was performed. Differences
were considered significant at 𝑃 < 0.05.
3. Results
3.1. Uterine Weight and Plasma 17𝛽-Estradiol Levels. We
confirmed that the ovaries had been removed successfully in
the OVX and OVX + 17𝛽-estradiol groups. The body weight
on day 14 after wounding was 25.08 ± 0.90 g in the SHAM
group, 25.45 ± 0.38 g in the OVX group, and 25.33 ± 2.67 g
in the OVX + 17𝛽-estradiol group. The macroscopic and
histological features of the uterus are shown in Figures 1(a)
and 1(b). The uterine weight in the OVX + 17𝛽-estradiol
group was significantly greater than the uterine weights of
SHAM and OVX groups on day 14 (𝑃 < 0.01). There were no
significant differences between SHAM and OVX groups on
day 14 (Table 1). The plasma 17𝛽-estradiol level in the OVX +
17𝛽-estradiol groupwas significantly greater than those levels
of SHAM and OVX groups on day 14 (𝑃 < 0.01). There were
no significant differences between SHAM and OVX groups
on day 14 (Table 1), although in the OVX group, 4 out of 6
mice had plasma 17𝛽-estradiol levels under 10 pg/mL and, in
the SHAM group, 1 out of 6 mice did. Estrus and proestrus
were not observed in the SHAM group when we observed
smears of the SHAMmice before euthanizing them.
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Table 1: Plasma 17𝛽-estradiol levels and uterine weight.
SHAM OVX OVX + 17𝛽-estradiol
17𝛽-estradiol (pg/mL) 11.3 ± 1.0∗∗ 10.8 ± 1.8∗∗ 27.7 ± 7.7
Uterine weight (mg) 35.0 ± 9.0∗∗ 34.0 ± 16.0∗∗ 122.0 ± 21.0
Values are expressed as mean ± SD, 𝑛 = 6 for each group, ANOVA, Tukey-Kramer. ∗∗𝑃 < 0.01 with respect to the OVX + 17𝛽-estradiol group.
3.2. Wound Area. In the SHAM group, wound areas
increased for 2 days and then decreased rapidly until day 8,
after which they decreased slowly until day 14 (0.15 ± 0.08,
ratio of wound area to initial wound area on day 14).The ratio
of wound area to initial wound area of 5 out of 12 wounds
reached a ratio of 0.1 to the initial wound area on day 14.
In the OVX group, wound areas increased for 2 days and
then decreased rapidly until day 9, after which they decreased
slowly until day 14 (0.24 ± 0.15). The ratio of wound area
to initial wound area of none out of 12 wounds reached a
ratio of 0.1 on day 14. On the other hand, in the OVX + 17𝛽-
estradiol group, wound area increased only for 1 day and then
decreased rapidly until day 11, after which it decreased slowly
until day 14 (0.08 ± 0.03). The ratio of wound area to initial
wound area of 9 out of 12 wounds reached a ratio of 0.1 on
day 14. The ratio of wound area in the OVX + 17𝛽-estradiol
group was significantly smaller than that of the OVX group
on days 4 and 11–14 (𝑃 = 0.0397, 0.0203, 0.0065, 0.0024,
and 0.0014, resp.). There were no significant differences of
the ratio of wound area between OVX + 17𝛽-estradiol and
SHAM groups, or between SHAM and OVX groups on days
0–14. However, the mean ratio of wound area in the OVX
group was larger throughout the whole period, except for
the first day (Figure 2(b)). The number of wounds reaching
a ratio of wound area of 0.1 on day 14 after wounding was
significantly different between SHAM and OVX groups and
between OVX and OVX + 17𝛽-estradiol groups (𝑃 = 0.0373
and 0.0003, resp.), but there were no significant differences
between SHAM and OVX + 17𝛽-estradiol groups.
3.3. Neutrophils, Macrophages and Plasma TNF-𝛼 Levels. The
number of neutrophils in the OVX + 17𝛽-estradiol group was
significantly smaller than that in the OVX group on day 3
(𝑃 = 0.0326). There were no significant differences between
OVX + 17𝛽-estradiol and SHAM groups or between SHAM
and OVX groups on day 3, and there were no significant
differences among the three groups on day 7 (Figure 3(a)).
Thenumbers of neutrophils significantly decreased fromdays
3 to 7 in the OVX and OVX + 17𝛽-estradiol groups (𝑃 =
0.0137 and 0.0145, resp.).
The number of macrophages in the OVX + 17𝛽-estradiol
group was significantly smaller than that in the OVX group
on day 3 (𝑃 = 0.0012). There were no significant differences
betweenOVX+ 17𝛽-estradiol and SHAMgroups, or between
SHAM and OVX groups on day 3, and there were no
significant differences among the three groups on day 7
(Figure 3(c)). The number of macrophages decreased in the
OVX group from days 3 to 7 but remained unchanged in the
SHAM and OVX + 17𝛽-estradiol groups.
There were no significant differences of plasma TNF-𝛼


























































Figure 2: Macroscopic wound healing. (a) Four mm diameter
wounds were produced and healing was recorded by photography.
Bar 5mm. (b) The ratios of wound areas to initial area on day 0 are
shown on line graphs for each day.There were significant differences
between the OVX + 17𝛽-estradiol and OVX groups on days 4 and
11–14. However, there were no significant differences between the
SHAM and OVX groups or between the SHAM and OVX + 17𝛽-
estradiol groups. Values are expressed as mean ± SD, 𝑛 = 12,
for each group, ANOVA, Tukey-Kramer, ∗𝑃 < 0.05: OVX versus
OVX + 17𝛽-estradiol.
Plasma TNF-𝛼 levels in the SHAM and OVX + 17𝛽-estradiol
groups decreased from days 3 to 7, with a significant decrease
in the OVX + 17𝛽-estradiol group (𝑃 = 0.0233), but it
remained unchanged in the OVX group.
3.4. Re-Epithelialization, Collagen Deposition, and Wound
Contraction. On day 3, new epithelium appeared from the






























































































































Figure 3: Inflammatory cells and plasma TNF-𝛼 levels. (a) The number of neutrophils per mm2. The number of neutrophils in the OVX
+ 17𝛽-estradiol group was significantly smaller than that in the OVX group on day 3. (b) Neutrophils (arrows) stained with antineutrophil
antibody were observed in wound tissue on days 3 and 7. Bar 20 𝜇m. (c)The number of macrophages per mm2. The number of macrophages
in the OVX + 17𝛽-estradiol group was significantly smaller than that in the OVX group on day 3. (d) Macrophages (arrows) stained with
anti-Mac-3 antibody were observed in wound tissue on days 3 and 7. Bar 20𝜇m. (e) Systemic TNF-𝛼 levels, determined by ELISA on serum
samples. There were no significant differences between the three groups on days 3 and 7. Values are expressed as mean ± SD, 𝑛 = 4-5 for each
group, ANOVA, t-test, or Tukey-Kramer; ∗𝑃 < 0.05, ∗∗𝑃 < 0.01: OVX versus OVX + 17𝛽-estradiol.
wound edge. It gradually covered the wound surface along
with wound healing. By day 11, new epithelium completely
covered the wound surface in theOVX+ 17𝛽-estradiol group,
but 1 out of 5 wounds was not completely covered in the
SHAMandOVX groups. By day 14, the surfaces of all wounds
in the three groups were covered with new epithelium.
However, there were no significant differences among the
three groups on days 3–14 (Figure 4(a)).
Collagen deposition became thick and had a high density
with the progression of wound healing in the three groups.
There were no significant differences among the three groups
on days 7–14, but that in the OVX + 17𝛽-estradiol group
tended to be larger than that in the OVX group on days 7 and
11 (𝑃 = 0.0648 and 0.0799, resp.) (Figure 4(c)).
A few myofibroblasts were observed at the wound site in
the three groups on day 7. By day 11, many myofibroblasts





















































































































































Figure 4: Re-epithelialization, collagen deposition, and wound contraction. (a) Proportion of no re-epithelialization. There were no
significant differences between the three groups on days 3–14. (b) Hematoxylin and eosin sections on day 7. Bar 500𝜇m. (c) The ratio of
collagen fibers. There were no significant differences between the three groups, although that in the OVX + 17𝛽-estradiol group tended
to be increased compared with that in the OVX group on days 7 and 11. (d) Azan-stained sections on day 7. Bar 500 𝜇m. (e) The ratio of
myofibroblasts. The ratio of myofibroblasts in the OVX + 17𝛽-estradiol group increased significantly compared with that in the OVX group
on day 11. However, there were no significant differences between OVX + 17𝛽-estradiol and SHAM groups or SHAM and OVX groups. (f)
Myofibroblasts stained with anti-𝛼-SMA antibody were observed in granulation tissue on day 11. Bars 500𝜇m (SHAM), 1000 𝜇m (OVX),
and 200 𝜇m (OVX + 17𝛽-estradiol). Note a bridge-like structure (arrows) formed by the myofibroblasts. Values are expressed as mean ± SD,
𝑛 = 4-5 for each group, ANOVA, Tukey-Kramer; ∗𝑃 < 0.05: OVX versus OVX + 17𝛽-estradiol.
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were observed in the granulation tissue in the three groups,
building bridge-like structures. They had almost completely
disappeared by day 14, with no detection in the three groups.
The ratio of myofibroblasts in the OVX + 17𝛽-estradiol group
was significantly larger than that in the OVX group on day 11
(𝑃 = 0.0426). However, there were no significant differences
between OVX + 17𝛽-estradiol and SHAM groups or between
SHAM and OVX groups on days 7–14 (Figure 4(e)).
4. Discussion
In the present study, the ratio of wound area in the OVX +
17𝛽-estradiol group was significantly smaller than that in the
OVX group on days 4 and 11–14 after wounding. This shows
that exogenous, continuous 17𝛽-estradiol administration is
effective for decreasing wound area in 20-week OVX female
mice. This agrees with previous research that cutaneous
wound healing in OVX mice is promoted by exogenous
estrogen treatment via a decrease of wound area [5, 8, 12–
14]. On the other hand, in the present study, the ratio of
wound area was not significantly different between SHAM
and OVX + 17𝛽-estradiol groups. The same result can be
assumed from graphs in previous research papers, although
they do not clearly show that cutaneous wound healing in
SHAM mice was not delayed compared with that in OVX
mice administered 17𝛽-estradiol at the age of 8–10 weeks [9–
11]. Moreover, in the present study, the ratio of wound area
was also not significantly different between SHAM and OVX
groups. This contradicts previous research that cutaneous
wound healing in OVXmice was delayed compared with that
in SHAMmice [5, 6, 8–14]. However, the number of wounds
reaching a ratio of wound area of 0.1 on day 14 after wounding
in the present study in the SHAM group was significantly
larger than that in the OVX group.This shows that cutaneous
wound healing in SHAM mice is promoted compared with
that in OVX mice by physiological estrogen. From these
findings, it is assumed that cutaneous wound healing in OVX
mice is the most delayed, and cutaneous wound healing
in OVX mice with exogenous, continuous 17𝛽-estradiol
administration is themost promoted,while cutaneouswound
healing in SHAM mice is intermediate between these two
groups. These findings indicate that exogenous, continuous
17𝛽-estradiol administration is more effective for cutaneous
wound healing than the natural physiological 17𝛽-estradiol
that fluctuates with estrus [19].
These differences in cutaneous wound healing among
OVX, SHAM, andOVX+ 17𝛽-estradiol groups in the present
study cannot necessarily be interpreted by the present results:
the ratio of re-epithelialization, the numbers of neutrophils
and macrophages, the level of TNF-𝛼, and the ratios of
myofibroblasts and collagen deposition. Previous researchers
reported that the physiological level of 17𝛽-estradiol and
exogenous, continuous 17𝛽-estradiol administration after
OVX promoted cutaneous wound healing by promoting re-
epithelialization [5, 9, 11–14], decreasing local numbers of
neutrophils and macrophages [8–12, 14] as well as wound
level of TNF𝛼 [8–12], and promoting collagen deposition [5].
In addition, Emmerson et al. reported that smooth muscle
action (SMA) was reduced in day 7 wound tissue from OVX
mice compared with that of wild-type mice, which have the
physiological level of 17𝛽-estradiol [13]. On the other hand, in
the present study, although there were significant differences
only between OVX and OVX + 17𝛽-estradiol groups—the
numbers of neutrophils and macrophages in the OVX +
17𝛽-estradiol group were significantly smaller than those in
the OVX group on day 3, and the ratio of myofibroblasts
in the OVX + 17𝛽-estradiol group increased significantly
more than that of the OVX group on day 11—there were
no significant differences in the ratios of collagen deposition
and re-epithelialization or the level of TNF-𝛼 between OVX
and OVX + 17𝛽-estradiol groups. However, there were no
significant differences of these factors between OVX and
SHAM groups. These findings may indicate that exogenous,
continuous 17𝛽-estradiol administration is more effective
than the natural physiological estrogen that fluctuates over
the course of an estrous cycle, as we have discussed for the
wound area.
However, from these findings, the following question
arises. Why were there no significant differences between
OVX and SHAM mice? Previous research evaluated the
effects of estrogen on cutaneous wound healing using 8–10-
week young femalemice in comparison amongOVX, SHAM,
and OVX with exogenous 17𝛽-estradiol administration. In
the present study, in contrast to previous research, we used
aged 24-week mice. Mills et al. demonstrated that cutaneous
wound healing in oldmalemice was delayed by extending the
wound area, compared with that in young male mice [20].
Hardman and Ashcroft reported, from a microarray study,
that 78% of differentially expressed genes were estrogen-
regulated, while only 3% were age-associated [21].The results
in the present study suggest that, although exogenous, con-
tinuous 17𝛽-estradiol administration influences cutaneous
wound healing, the influence of age cannot be disregarded
since the effect of the SHAM group with physiological estro-
gen on cutaneous wound healing seems to be intermediate
between the effects of the OVX and OVX + 17𝛽-estradiol
groups. Therefore, we will conduct further research using an
older mouse model and attempt to evaluate the influence of
17𝛽-estradiol and advanced age on cutaneous wound healing
in the near future.
5. Conclusions
Weclarified that exogenous, continuous 17𝛽-estradiol admin-
istration has beneficial effects on wound area, inflammatory
cells, and myofibroblasts during cutaneous wound healing.
Therefore, our research suggests that exogenous, continuous
17𝛽-estradiol administration also promotes cutaneouswound
healing in 24-week OVX female mice by reducing wound
area, shortening inflammatory response, and promoting
wound contraction. However, it is unclear whether the effect
of exogenous, continuous 17𝛽-estradiol administration on
wound healing outweighs the delay of wound healing due to
advanced age.
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